ADMA Biologics, Inc.
Bear Case (25th pct.)
-47.8% vs price
Base Case (Median)
-25.5% vs price
Bull Case (75th pct.)
0.7% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $4.63 | -50.4% | High (40%) |
| PE Comparable | $15.58 | 66.8% | Medium (25%) |
| Graham Number | $5.62 | -39.9% | Medium (40%) |
| EV/EBITDA | $8.30 | -11.1% | Medium (20%) |
| EV/FCF | $9.78 | 4.7% | Medium (20%) |
| Earnings Power Value | $4.19 | -55.2% | Medium (50%) |
Based on 6 out of 8 methods, ADMA appears fairly valued at the current price of $9.34. The base case fair value of $6.96 implies 25.5% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.